NANOVIRICIDES, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 1 CONTROLS DRIVE, SHELTON, CT, 06484
Mailing Address 1 CONTROLS DRIVE, SHELTON, CT, 06484
Phone (203) 668-5580
Fiscal Year End 0630
EIN 760674577
Financial Overview
FY2025
-$9.47M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-3 Shelf registration for future offerings | December 15, 2025 | View on SEC |
| 8-K Current report of material events | November 26, 2025 | View on SEC |
| 8-K Current report of material events | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
| 424B5 Prospectus supplement | November 12, 2025 | View on SEC |
| 424B5 Prospectus supplement | November 12, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | October 8, 2025 | View on SEC |
| 8-K Current report of material events | October 1, 2025 | View on SEC |
| 10-K Annual financial report | September 29, 2025 | View on SEC |
| 10-Q Quarterly financial report | May 15, 2025 | View on SEC |
Annual Reports
10-K September 29, 2025
- Expanded pipeline to 40+ virus treatments including NV-HHV-1 Cream (Phase I safety done) and NV-387 (effective against MPox in animals).
- Fully integrated lab with BSL2 certification and 10x faster in-house drug screening.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.